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Abstract
Introduction: Signal transducer and activator of transcription 3 (STAT3) is over-activated or phosphorylated in
breast cancers. The hyper-phosphorylation of STAT3 was attributed to either up-regulated phosphorylation by
several tyrosine-kinases or down-regulated activity of phosphatases. Although several factors have been identified
to phosphorylate STAT3, it remains unclear how STAT3 is dephosphorylated by PTPMeg2. The aim of this study
was to determine the role of PTPMeg2 as a phosphatase in regulation of the activity of STAT3 in breast cancers.
Methods: Immunoprecipitation assays were used to study the interaction of STAT3 with PTPMeg2. A series of
biochemistry experiments were performed to evaluate the role of PTPMeg2 in the dephosphorylation of STAT3.
Two breast cancer cell lines MCF7 (PTPMeg2 was depleted as it was endogenously high) and MDA-MB-231
(PTPMeg2 was overexpressed as it was endogenously low) were used to compare the level of phosphorylated
STAT3 and the tumor growth ability in vitro and in vivo. Samples from breast carcinoma (n = 73) were subjected
to a pair-wise Pearson correlation analysis for the correlation of levels of PTPMeg2 and phosphorylated STAT3.
Results: PTPMeg2 directly interacts with STAT3 and mediates its dephosphorylation in the cytoplasm. Over-
expression of PTPMeg2 decreased tyrosine phosphorylation of STAT3 while depletion of PTPMeg2 increased its
phosphorylation. The decreased tyrosine phosphorylation of STAT3 is coupled with suppression of STAT3
transcriptional activity and reduced tumor growth in vitro and in vivo. Levels of PTPMeg2 and phosphorylated
STAT3 were inversely correlated in breast cancer tissues (P = 0.004).
Conclusions: PTPMeg2 is an important phosphatase for the dephosphorylation of STAT3 and plays a critical role in
breast cancer development.
Introduction
STAT3 is crucial in regulating cell growth, differentia-
tion and survival in response to many extracellular cyto-
kines and growth factors [1,2]. Hyper-phosphorylation
of STAT3 has been observed in a variety of hematopoie-
tic malignancies and solid tumors, including breast can-
cer [3,4]. In general, latent cytoplasmic STAT3 becomes
activated through phosphorylation at the residue Tyr705
by Janus Associated Kinase (JAK) or growth factor
receptor-associated tyrosine kinase (Src). Phosphorylated
STAT3 dimerizes through a reciprocal Src homology 2-
phospho-tyrosine interaction and accumulates in the
nucleus, where it activates the transcription of a wide
array of genes, including Bcl-xl, cyclin D1, c-Myc and
SOCS3 [5].
Most studies attributed the hyper-phosphorylation of
STAT3 to over-activation of JAK or Src kinase. How-
ever, STAT3 phosphorylation is also tightly regulated by
a process of dephosphorylation, which is mediated by
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protein tyrosine phosphatases (PTPs). A line of evidence
has been provided that phosphatases play an important
role in numerous signaling pathways that regulate cell
proliferation, apoptosis, adhesion, and migration [6].
PTPs are a large and structurally diverse family of
enzymes that catalyze the dephosphorylation of phos-
phorylated proteins. Previous studies indicated that pro-
tein tyrosine phosphatase 1B (PTP1B) modulates
cytokine signaling pathways by dephosphorylating JAK2,
TYK2, STAT5a/b [7,8], and STAT6 [9] in the nucleus.
Other studies demonstrated that STAT1, STAT3 and
STAT5 are dephosphorylated by SHP2 [10-12] and TC-
PTP (PTPN2) [13,14] in the nucleus. It appears that
STAT proteins can be dephosphorylated by different
phosphatases both in the cytoplasm and nucleus [15].
Importantly, aberrant expression of PTPs leads to
hyper-phosphorylation of STATs in the development of
human diseases, including cancers, diabetes, inflamma-
tion and infectious diseases [16,17].
PTPMeg2 (PTPN9, protein tyrosine phosphatase, non-
receptor type 9), a cytoplasmic phosphatase cloned with
sequence homology to retinaldehyde-binding protein
and yeast SEC14p, is reported to dephosphorylate
EGFR, ErB2 and Fox-1 [18-20]. Functional studies indi-
cated that PTPMeg2 promotes intracellular secretary
homotypic vesicle fusion in hematopoietic cells [21],
regulates embryonic development [22] and controls
expansion of erythroid cells [23]. Other studies demon-
strated that PTPMeg2 regulates insulin production, beta
cell growth or insulin signaling by reducing insulin
receptor dephosphorylation in type II diabetes [18,19].
Recently, two studies showed that PTPMeg2 promotes
dephosphorylation of EGFR and ErbB2 thereafter to
impair the activation of STAT3 [20] and STAT5 [20,24]
in breast cancer cells. However, it remains unknown
whether PTPMeg2 directly targets STAT3. In this study,
we demonstrated that PTPMeg2 dephosphorylates
STAT3 at the Tyr705 residue by a direct interaction.
We propose that PTPMeg2 is a novel direct phospha-
tase for STAT3.
Materials and methods
Cell culture, reagents and plasmid construction
MCF7, MDA-MB-231, and HEK293T cells were
obtained and characterized by a cytogenetic analysis by
American Type Culture Collection (ATCC) and main-
tained in this lab according to the recommendation of
ATCC. The cell lines were characterized in this lab by
morphological analysis before using for experiments.
The v-Src/NIH3T3 cell line was a gift from Dr. H Yu at
City of Hope Comprehensive Cancer Center, California,
USA and was characterized by morphological analysis in
this lab according to her recommendation. The stable
cell line for depletion of PTPMeg2 by shRNA was
generated in this lab based on MCF7 and characterized
by morphological analysis and the expression of targeted
gene was characterized by a Western blot. The cells
were cultured in DMEM medium supplemented with
10% fetal bovine serum in 5% CO2 astrosphere in 37°C.
The mouse hepatic cell lines STAT3-/- (KO) and STAT3
+/+ (WT) derived from STAT3 conditional knockout
and wild-type mice were also cultured in DMEM
medium.
Anti-sera against PTPMeg2 were generated by immu-
nizing rabbits with purified GST-PTPMeg2 (1-1779)
proteins in ZJ Zhao’s lab. Anti-Myc (9E10), anti-HA (F-
7), anti-GFP (FL), anti-pSTAT3(Tyr705, B-7), anti-
pSTAT3(Ser727), anti-STAT3 (F-2) and anti-STAT3 (C-
20) antibodies, and protein G/A plus agarose beads were
purchased from Santa Cruz Biotechnology, and anti-b-
Actin (AC-15) antibody from Sigma. MG132 and leu-
pepstin were purchased from Amresco (AMRESCO Inc.
OH), and human recombinant IL-6 and IL-6 receptor
from B&D (B&D SYSTEM, USA). Plasmids including
GST-STAT3, pXJ40-STAT3, and its deletions were
kindly provided by Dr. Xinmin Cao [25]. Expression
vectors for human PTPMeg2 and PTPMeg2C515S or
deletion mutants were constructed based on pcDNA3.1-
Myc or pEFneo-Myc. Other plasmids involved in this
study were stored in the lab.
Luciferase assay
MCF7 cells were plated in 24-well plates the day before
transfection. An amount of 0.1 μg of reporter plasmid
pAPRE-luc or M67-luc together with 5 ng of an internal
control plasmid pRL-TK was transfected. Constructs
expressing STAT3, PTPMeg2 and its mutants were co-
transfected at an amount of 0.4 μg per well. To deplete
endogenous PTPMeg2, 0.8 μg of vectors with shRNA tar-




TA-3’, shRNA3: 5’-GATCCCTAGAGTGAAGCT AACAA
TTCAAGAGATTGTTAGCTTCACTCTAGTTTA-3’) in
pSilencer-4.1 was transfected. Twenty-four hours after
transfection, luciferase assays were performed with a dual-
luciferase reporter assay system (Vigofect Inc. Beijing,
China) and the luciferase activity was normalized by firefly
against the renilla luciferase activity.
Western blot, GST pull down and immunoprecipitation
assay
Proteins were analyzed by SDS-PAGE and Western blot
[26]. For immunoprecipitation experiments, HEK293T
cells grown in 60 mm dishes were transfected with indi-
cated expression plasmids and were lysed in cell lysis
buffer (20 mM Tris-Cl, pH 7.6, 150 mM NaCl, 5 mM
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EDTA, 10 mM MgCl2, 0.5% NP40, 10% glycerol, 1 mM
DTT, 0.1 mM Na3VO4, 1 mM phenylmethylsulfonyl
fluoride, 1 μg/ml aprotinin, 1 μg/ml leupeptin, and 1
μg/ml pepstatin) for 30 min on ice, and then the lysates
were centrifuged at a maximum speed for 15 min.
Supernatants of cell lysates were incubated with 2 μg of
indicated antibodies overnight at 4°C, and 30 μl of pro-
tein IgG/A agarose plus beads were added for binding
for 4 h at 4°C. Beads were washed with cell lysis buffer
(containing 0.1 mM vanadium) 4 times and bound pro-
teins were eluted with 2 × loading sample buffer and
analyzed by Western blot with indicated antibodies. For
GST-pull down assays, the procedure was similar to that
in immunoprecipitation experiments except that GST
beads were used and washed by PBST buffer.
In vitro dephosphorylation assay
GST-PTPMeg2 WT and GST-PTPMeg2CS proteins
were expressed and purified as described previously
[27]. Phosphorylated Flag-STAT3 was prepared from
HEK 293T cells transfected with Flag-STAT3 for 48 h
and then stimulated with IL-6 for 30 min. Purified phos-
phorylated Flag-STAT3 was incubated with GST and
GST-PTPMeg2 WT or GST-PTPMeg2CS proteins at
37°C for 30 min with PTPase reaction buffer (25 mM
Tris-Cl, pH 7.5, 2.5 mM EDTA, 1 mM EGTA, 1 mg/ml
BSA, 10 μM TPCK, 1 mM Benzamidine, 5 mM DTT, 1
mM phenylmethylsulfonyl fluoride, 1 μg/ml aprotinin, 1
μg/ml leupeptin, and 1 μg/ml pepstatin). The depho-
sphorylation reaction was terminated by directly boiling.
Proteins were separated with SDS-PAGE and analyzed
with an anti-pSTAT3 and anti-Flag antibodies by a
Western blot.
Immunocytochemistry
Cells were seeded on glass coverslips for 24 h and sub-
jected to serum-starvation for 18 h before treatments
with IL-6 for 30 min. Cell was fixed in 4% paraformalde-
hyde for 20 min at 4°C and permeabilized in 0.3% Tri-
ton X-100 for 15 min. Cells were blocked with 10%
normal rabbit serum at room temperature and incu-
bated in primary antibody overnight at 4°C. Primary
antibodies used were an anti-PTPMeg2 or an anti-Flag
antibody. Secondary antibodies used were FITC-conju-
gated and TRITC-conjugated IgG. Nucleus was stained
with DAPI.
Cell growth experiment
MCF7 cells stably transfected with the shPTPMeg2 plas-
mid, or MDA-MB-231 or mouse hepatic STAT3 KO
cells infected with an adenovirus for over-expression of
PTPMeg2, were seeded on 96-well plates at a density of
1000 cells/well in triplicate. Cells were cultured for dif-
ferent times and 5 g/L of MTT was added 4 h before
termination of cell growth. The purple blue sediment
was dissolved in 150 μl of DMSO before harvest. The
relative optical density (OD)/well was determined at
wavelength of 570 nm in a WELLSCAN MK3 ELIASA
(Lab systems, Dragon, Finland) using a 630 nm refer-
ence filter. Cell growth curve was drawn according to
the average of OD570-OD630.
Xenograft tumor model
Exponentially growing MCF7 cells were stably trans-
fected with the PTPMeg2 shRNA vector and MDA-MB-
231 were infected with the adenovirus or retrovirus and
v-Src/NIH3T3 cells with the adenovirus for over-expres-
sion of PTPMeg2. Cells were suspended in 1 ml physio-
logical saline for preparation of injection into mice.
BALB/c-nu/nu mice at 5 weeks of age were subjected to
bilateral subcutaneous injections with 1.0 × 107 (MCF-
7) or 5.0 × 106 (MDA-MB-231) or 5.0 × 105 (v-Src/
NIH3T3) cells in a volume of 0.1 ml saline. Tumor
volume defined as (length × width2)/2 was measured
every two days with a caliper up to study termination.
Tumor growth curves were drawn according to the
average of tumor volumes (mm3). All animal experi-
ments were performed in accordance with the institu-
tional animal experiment guidelines.
Patient samples and immunohistochemistry
The formalin-embedded tissue samples from 73 patients
with breast carcinomas diagnosed between 2008 and
2010 were obtained from the Surgical Pathology in the
TangShan People’s Hospital. All breast cancer specimens
from female patients were obtained from clinical sur-
gery. Information of age, histological type, differentiation
grade, and lymph node metastasis of breast carcinomas
were obtained from the Surgical Pathology Files in the
hospital. The clinicopathological diagnosis on the tumor
status was evaluated by the clinical pathologists in the
hospital. All samples used in the study were approved
by the TangShan People’s Hospital Ethical Committee
under the guidance of tissue collection procedure with
informed consent.
Sections of formalin-fixed breast carcinoma tissues
were treated with 0.3% hydrogen peroxidase/methanol
and incubated with primary antibodies followed by incu-
bation with secondary antibodies (biotin-labeled; Santa
Cruz) and third antibodies (peroxidase-labeled; Santa
Cruz). Samples were developed using DAB as substrates
(Santa Cruz). Scoring criteria for tumor degrees as
reported previously were used [28]. Briefly, the grade
was classified as 0 for negative, 1 for weak (< 10%), 2
for moderate (10-25%), 3 for strong (26-75%) and 4 for
very strong (> 75%) staining according to percentage of
positively staining cells. The staining index was subse-
quently obtained by multiplication of the proportion
Su et al. Breast Cancer Research 2012, 14:R38
http://breast-cancer-research.com/content/14/2/R38
Page 3 of 13
and intensity and calculated index was finally assessed
by a simplified score (score 0, index 0-1; score 1, index
2-4; score 2, index 6-8; score 3, index 9-12). Samples
with staining score of at least 1 were classified as posi-
tive staining, score 2 and 3 were strong positive staining.
The percentage of pSTAT3 nuclear positive cells were
used to classify the grade of its expression as negative (<
5%), weak (6-50%), and strong (51-100%).
Statistical analysis
All experiments were repeated at least three times. The
Student’s t test was used to evaluate the significance of
differences between experimental and control groups.
Data were analyzed by one-way ANOVA with SPSS13.0
(SPSS, Int, Chicago, IL). Frequencies of PTPMeg2,
STAT3 and pSTAT3 expressions among cancer samples
were analyzed by the x2 test with a modification by the
Fisher’s exact test to account for frequency values < 5.
The correlation between protein levels was evaluated by
the pair-wise Pearson correlation coefficient and by bi-
dimensional hierarchical clustering. All Ps reported were
two-sided. Significance was defined at the level of P ≤
0.05.
Results
PTPMeg2 interacts with STAT3 in mammalian cells
To search for negative regulators of STAT3, we exam-
ined the possibility of its interaction with different phos-
phatases, and PTPMeg2 was identified as a potential
interacting protein. To confirm the interaction, Myc-
PTPMeg2 and Flag-STAT3 were co-expressed in HEK
293T cells and co-immunoprecipitation and GST pull-
down experiments were performed. The results showed
that PTPMeg2 interacts with STAT3 in vitro (Figure 1A
and 1B). Interestingly, we observed that PTPMeg2 pre-
ferentially interacted with STAT3 as it had either a
weak or no interaction with STAT5 or STAT1 (Figure
1C). An in vivo interaction of endogenous PTPMeg2
and STAT3 proteins was observed in the mouse brain
tissue (Figure 1D, left panel) and breast cancer MCF7
cells (Figure 1D, right panel). All these results suggested
that PTPMeg2 interacts with STAT3 under physiologi-
cal and pathological conditions.
PTPMeg2 interacts with both phosphorylated and
unphosphorylated forms of STAT3
To determine if the interaction of PTPMeg2 with STAT3
is regulated by cytokines, HEK 293T cells transfected with
Flag-STAT3 and Myc-PTPMeg2 were stimulated by IL-6
for 30 min. A reciprocal immunoprecipitation experiment
indicated that the interaction of PTPMeg2 and STAT3
was increased dramatically under stimulation of IL-6
(Figure 1E). Interestingly, we observed a strong band of
phosphorylated STAT3 in a complex precipitated with an
anti-Myc antibody (for Myc-PTPMEG2) (Figure 1E).
Consistently we observed that IL-6 induced the interaction
of endogenous STAT3 and PTPMeg2 in MCF7 cells (Fig-
ure 1F). These results suggest that PTPMeg2 interacts
with the phosphorylated form of STAT3 (pSTAT3). Based
on the observation that PTPMeg2 interacts with STAT3
in the absence of IL-6, we concluded that PTPMeg2 inter-
acts with both the phosphorylated and unphosphorylated
STAT3.
To reveal the cellular location of the PTPMeg2/
STAT3 complex, we performed an immunofluorescence
staining assay in MCF7 cells transfected with STAT3
and PTPMeg2. The results showed that STAT3 was
located in the cytoplasm under a quiet condition, but
translocated into the nucleus after IL-6 stimulation
(Figure 1G, b2-b3). When STAT3 was co-expressed
together with PTPMeg2, a notable co-localization of the
two proteins in the cytoplasm was observed (Figure 1G,
c3). Interestingly, we observed that STAT3 remained in
the cytoplasm under the stimulation of IL-6 when
PTPMeg2 was co-expressed (Figure 1, 2, 3). This result
suggests that PTPMeg2 blocks the translocation of
STAT3 from the cytoplasm into the nucleus upon IL-6
stimulation. To support this notation, a mutant
PTPMeg2CS, which lost the ability to dephosphorylate
STAT3, failed to block STAT3 localization into the
nucleus in response to IL-6 stimulation (Figure 1, 2, 3).
These results suggest that STAT3 colocalizes with
PTPMeg2 in the cytoplasm and overexpression of
PTPMeg2 inhibits the translocation of STAT3 upon
cytokine stimulation.
PTPMeg2 enhances dephosphorylation of STAT3
Our observation that over-expression of PTPMeg2
blocks STAT3 translocation implied that PTPMeg2 may
regulate STAT3 phosphorylation. Since PTPMeg2 is a
phosphatase, we determined to examine whether
PTPMeg2 dephosphorylates STAT3. To this end,
HEK293T cells were transfected with Flag-STAT3 and
Myc-PTPMeg2 plasmids under IL-6 treatment for 30
min. The results showed that the level of pSTAT3 was
decreased when PTPMeg2 was co-expressed with
STAT3 (Figure 2A). In contrast, transfection of mutant
PTPMeg2CS failed to decrease the level of pSTAT3
(Figure 2A). To examine whether the decreased level of
pSTAT3 is induced by a dephosphorylation or protein
degradation process, the level of pSTAT3 was examined
after withdrawal of IL-6 and in the presence of MG132,
an inhibitor of proteosome. Results showed that the
level of pSTAT3 was decreased much more quickly
when PTPMeg2 was over-expressed than that without
PTPMeg2 (Figure 2B). At the same time, the level of
pSTAT3 remained unchanged in the presence or
absence of MG132 (Figure 2B). These dada indicated
Su et al. Breast Cancer Research 2012, 14:R38
http://breast-cancer-research.com/content/14/2/R38
Page 4 of 13
AD FE










Mouse brain MCF7 cells













































Merged + DAPI Merged + DAPI Merged + DAPI
PTPMeg2CS PTPMeg2CS
STAT3 STAT3
Merged + DAPI Merged + DAPI
STAT3 STAT3+PTPMeg2WT STAT3+PTPMeg2CS













































































Figure 1 PTPMeg2 interacts with STAT3. (A) PTPMeg2 was co-immunoprecipitated with STAT3 in mammalian cells. Lysates prepared from
HEK293T cells expressing Flag-STAT3 and Myc-PTPMeg2 were precipitated with an anti-Flag antibody and the precipitants were blotted by an
anti-Myc antibody. (B) STAT3 interacts with PTPMeg2 physically in vitro. GST or GST-STAT3 fusion proteins were mixed with the Myc-PTPMeg2
prepared from cells (C) PTPMeg2 preferentially interacts with STAT3. Myc-PTPMeg2 was co-expressed with Flag-tagged STAT3 (S3), STAT1 (S1) or
STAT5a (S5a) in 293T cells. (D) PTPMeg2 interacts with STAT3 in vivo. Lysates from the mouse brain tissue and breast cancer MCF7 cells were
used in co-immunoprecipitation assays to demonstrate the endogenous protein interaction with an anti-STAT3 antibody (C20) and anti-PTPMeg2
rabbit polyclonal antibody. (E) PTPMeg2 interacts with phosphorylated STAT3. A reciprocal immunoprecipitation assay was performed with an
anti-Myc antibody or an anti-Flag antibody for the lysates of HEK293T cells under IL-6 stimulation for 30 min. (F) IL-6 induces the interaction of
STAT3 and PTPMeg2 in vivo. An immunoprecipitation assay was performed using the endogenous proteins in MCF7 cells stimulated by IL-6 for
30 min. (G) PTPMeg2 decreases the accumulation of pSTAT3 in the nucleus. MCF7 cells transfected with STAT3 and/or PTPMeg2 WT/CS were
treated without or with IL-6 for 30 min. Cells were immunostained with an anti-PTPMeg2 (FITC) and an anti-Flag antibody (TRITC, for Flag-STAT3).
DAPI was used for nuclear staining. Scale, 10 μm.
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Figure 2 PTPMeg2 enhances dephosphorylation of STAT3. (A) PTPMeg2 decreases the level of pSTAT3. Levels of pSTAT3(Tyr705) were
examined in the HEK293T cells transfected with Flag-STAT3 and different forms of PTPMeg2 in the presence or absence of IL-6 (10 ng/ml) for 30
min. (B) PTPMeg2 increases the dephosphorylation of STAT3. HEK293T cells were treated with IL-6 (10 ng/ml) for 30 min, followed by a
starvation (shown as withdrawal) for different times. (C) PTPMeg2 promotes the STAT3 dephosphorylation rate. HEK293T cells were treated with
IL-6 (10 ng/ml) for 30 min, followed by starvation for different times. The dynamic changes of the pSTAT3 (Tyr705) levels demonstrates the
dephosphorylation rate of STAT3. (D) PTPMeg2 mediates STAT3 dephosphorylation in a dose dependent manner. HEK293T cells were transfected
with Flag-STAT3 (2 μg/well) and different amounts of PTPMeg2 in a 6 well plate. (E) PTPMeg2 dephosphorylates STAT3 in vitro. Different
amounts of purified GST-PTPMeg2 (10, 5 and 2.5 μg/tube) was added to purified pSTAT3 in a PTPase buffer at 37°C for 30 min. pSTAT3 was
prepared in HEK293T cells transfected with Flag-STAT3 for 48 h and then stimulated with IL-6 for 30 min. (F) The PTP domain of PTPMeg2
contributes to STAT3 dephosphorylation. Myc-PTP domain, Myc-SEC domain and different deletions of PTPMeg2 were co-transfected with Flag-
STAT3 for 48 h before stimulation with 10 ng/ml IL-6 for 30 min.
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that PTPMeg2 induces dephosphorylation of pSTAT3
rather than its degradation. Furthermore, we showed
that over-expression of PTPMeg2 promoted the depho-
sphorylation of STAT3 at the residue Tyr 705 but had
no effect on the phosphorylation level of pSTAT3 at the
residue Ser727 (Figure 2C). The role of PTPMeg2 on
the dephosphorylation of pSTAT3 (Tyr705) was further
confirmed in a dosage dependent experiment (Figure
2D). These results suggested that ectopic expression of
PTPMeg2 regulates the tyrosine phosphorylation of
STAT3.
To further confirm the role of PTPMeg2 on depho-
sphorylation of STAT3, purified GST-PTPMeg2 and
GST-PTPMeg2CS fusion proteins were used to incubate
with pSTAT3 prepared from mammalian cells for an in
vitro phosphatase activity experiment. The results
showed that the tyrosine phosphorylation level of
STAT3 was dramatically reduced when GST-Meg2 pro-
tein was added in a dose dependent manner (Figure 2E).
As controls, addition of GST or GST-PTPMeg2CS had
no effect on the level of pSTAT3 (Figure 2E, lane 1 to

































































































































































































Figure 3 PTPMeg2 decreases the transcription activity of STAT3. (A) PTPMeg2 inhibits IL-6-stimulated STAT3 transcriptional activity.
Luciferase assays were performed using MCF7 cells with transient expression of Myc-PTPMeg2 and Flag-STAT3, transfected with APRE-Luc
reporter and pRL-TK (as an internal control). Relative luciferase activities were normalized with the internal control. Results are presented as mean
± SD from three independent experiments. (B) PTPMeg2 inhibits STAT3-mediated transcriptional activity in a dose dependent manner. Different
amounts of PTPMeg2 were co-expressed with STAT3 in the presence or absence of IL-6 stimulation. Different amounts of PTPMeg2CS were also
co-expressed with STAT3. (C) The PTP domain of PTPMeg2 inhibits the STAT3 transcriptional activity. Different domains and deletions of
PTPMeg2 were co-expressed with Flag-STAT3 in the MCF7 cells and luciferase assays were performed as above. (D) Depletion of PTPMeg2 results
in an enhanced STAT3 transcriptional activity. An shRNA targeting PTPMeg2 was co-expressed with STAT3 in MCF7 cells transfected with APRE-
Luc reporter and pRL-TK under stimulation of IL-6. Luciferase activities were assayed as above. (E) Levels of pSTAT3(Tyr705) and STAT3 were
examined in the MCF7 cells overexpressed and depleted PTPMeg2 in separated membranes from the same lysates. (F) PTPMeg2 has no effect
on the STAT1 transcriptional activity. M67 luciferase reporters were co-transfected into MCF7 cells with STAT1 and PTPMeg2, in the presence or
absence of IFN-gamma. Luciferase activities shown are mean ± SD of three independent experiments.
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PTPMeg2. To address whether the PTP domain of
PTPMeg2 has the phosphatase activity, the SEC domain,
PTP domain and mutations of different deletions
(ΔSEC, ΔPTP) were generated to examine the effect on
the level of pSTAT3. A Western blot result showed that
both PTP domain and ΔSEC domain had the ability to
dephosphorylate pSTAT3 (Figure 2F, lanes 4 and 5).
These data indicated that the PTP domain is responsible
for the phosphatase activity of PTPMeg2, which is in
consistency with the role of the PTP domain in other
phosphatases.
PTPMeg2 suppresses the transcriptional activation of
STAT3
We questioned whether PTPMeg2 regulates the tran-
scriptional activity of STAT3 based on its interaction
with STAT3. To this end, we used an APRE luciferase
reporter, which responds to STAT3 activation, to exam-
ine the effect of PTPMeg2 on STAT3 mediated tran-
scriptional activity. The results showed that over-
expression of PTPMeg2 in MCF7 cells resulted in a
decrease of the luciferase activity in response to over-
expressed STAT3 and stimulation of IL-6 (Figure 3A).
The inhibitory role of PTPMeg2 on the STAT3-
mediated luciferase activity was dose dependent (Figure
3B, left columns). Interestingly, when the mutant
PTPMeg2CS was increasingly expressed the STAT3-
mediated luciferase activity was increased (Figure 3B,
right columns). These results suggest that the mutant
PTPMeg2CS acts as a dominant negative antagonist of
endogenous PTPMeg2 in regulating STAT3 phosphory-
lation. In consistence, depletion of the PTP domain
impaired the activity of the phosphatase (Figure 3C).
Finally, we showed that depletion of PTPMeg2 by three
shRNAs increased the luciferase activity mediated by
STAT3 (Figure 3D) while these shRNAs dramatically
recovered the phosphorylation of the endogenous
STAT3 protein (Figure 3E). In contrast, over-expression
of PTPMeg2 had no effect on the transcriptional activity
of STAT1 in response to INF-gamma stimulation
(Figure 3F). These results indicate that PTPMeg2 inhi-
bits STAT3 activation with certain specificity.
PTPMeg2 inhibits breast cancer cell proliferation and
tumor growth in nude mice
Since STAT3 phosphorylation is highly related to
tumorigenesis, we attempted to examine whether
PTPMeg2 could affect tumor progression. For this pur-
pose, we used two human breast cancer cell lines MCF7
and MDA-MB-231. We observed that the endogenous
PTPMeg2 protein level was low in MDA-MB-231 cells
but high in MCF7 cells while the level of endogenous
pSTAT3 displayed a reversed trend (Figure 4A). There-
fore we determined to establish a gain-of-function
model in MDA-MB-231 cells and a loss-of-function
model in MCF7 cells.
To address the increased pSTAT3 was the cause of
decreased PTPMeg2, we stably depleted PTPMeg2 by
using an shRNA targeting PTPMeg2 in MCF7 cells. A
Western blot analysis showed that pSTAT3 was drama-
tically increased when PTPMeg2 was depleted (Figure
4B, right lane). Intriguingly, a cell proliferation experi-
ment result showed that the growth of MCF7 cells was
increased when PTPMeg2 was depleted (Figure 4C). An
in vivo tumor growth experiment in a xenograft tumor
model in mice showed that MCF7 cells with stable
depletion of PTPMeg2 formed larger tumors than mock
transfected cells (Figure 4D-E) and grew more rapidly
(Figure 4F). On the other hand, we over-expressed
PTPMeg2 in MDA-MB-231 cells using an adenovirus
expression system. The results showed that MDA-MB-
231 cells infected with the adenovirus expressing
PTPMeg2 had a lower level of endogenous pSTAT3
than the cells infected with a control adenovirus (GFP)
(Figure 4G, right lanes). And these cells grew much
more slowly (Figure 4H) and the cells formed smaller
sized tumors (Figure 4I-J) and had slower tumor growth
rate (Figure 4K), lower tumor weight (Figure 4J) and
slower tumor growth (Figure 4K). To further confirm
the inhibitory role of PTPMeg2 on tumor growth in a
moderate expression system, we used the retroviral sys-
tem to ectopically express PTPMeg2 (pMSCV/
PTPMeg2) in MDA-MB-231 cells. The results were
similar to that using the adenovirus expression system
(Figure 4L-N). All these results indicated that PTPMeg2
inhibits STAT3 phosphorylation directly and PTPMeg2
is a tumor suppressor.
To confirm the inhibitory role of PTPMeg2 on tumor
growth is depended on regulation of STAT3 phosphory-
lation, we used v-Src transformed NIH3T3 fibroblasts in
a xenograft tumor model. The result showed that v-Src
transformed cells had a much higher STAT3 phosphory-
lation level than non-transformed cells and over-expres-
sion of PTPMeg2 significantly decreased the level of
pSTAT3 (Figure 5A). Consistent with the decreased
level of pSTAT3, the tumor size (Figure 5B), weight
(Figure 5C) and tumor growth (Figure 5D) from v-Src
transformed cells were decreased when PTPMeg2 was
forcedly expressed. These data implied a correlation of
PTPMeg2-reduced tumor growth and the decreased
level of pSTAT3. To address whether pSTAT3 is a key
target by PTPMeg2, we examined the cell proliferation
ability in the STAT3 KO cells. A MTT experiment indi-
cated that overexpression of PTPMeg2 inhibited the cell
growth dramatically in wild-type cell but had no effect
in the STAT3 KO cells (Figure 5E-F), suggesting that
the inhibitory role of PTPMeg2 on the cell proliferation
is depended on STAT3. Together with the biochemical
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Figure 4 PTPMeg2 inhibits breast cancer cell proliferation and tumor growth in nude mice. (A) PTPMeg2 expression correlates with the
pSTAT3 level in breast cancer cells. The levels of pSTAT3, STAT3 and PTPMeg2 are shown. (B) Depletion of PTPMeg2 results in an increased level
of pSTAT3 and expression of downstream gene expression. An shRNA targeting PTPMeg2 was stably expressed in MCF7 cells (MCF7/
shPTPMeg2). Two downstream proteins CyclinD1 and Bcl-xL were examined. (C) Silencing PTPMeg2 increases the MCF7 cell proliferation. MCF7
stable cell lines were examined by an MTT assay. (D-F) Depletion of PTPMeg2 increases growth of tumors from MCF7 cells in nude mice. 1 × 107
MCF7 cells stably expressing shPTPMeg2 were injected s.c. into the right flanks of 6-week-old female nude mice (n = 6). Tumor weights (D),
xenograft tumors (E), tumor sizes (F) are shown. (G) Over-expression of PTPMeg2 inhibits pSTAT3 and expression of its targeted genes. MDA-MB-
231 cells were infected with Ad/PTPMeg2 or Ad/GFP. (H) Over-expression of PTPMeg2 inhibits MDA-MB-231 cell proliferation. MDA-MB-231 cells
were examined by an MTT assay. (I-K) Over-expression of PTPMeg2 represses tumor growth. Tumor formation was observed in nude mice
injected with 2 × 106 MDA-MB-231cells infected with Ad/PTPMeg2 or Ad/GFP. Xenograft tumors (I), tumor weights (J) and tumor volumes (K) are
shown. All the data were obtained from 6 Balb/c-nu nude mice. Tumor formation was examined in nude mice injected with 6 × 106 MDA-MB-
231cells infected with pMSCV/PTPMeg2 or pMSCV/vector virus. Xenograft tumors (L), tumor weights (M) and tumor volumes (N) are shown.
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Figure 5 The correlation of the PTPMeg2 expression and the pSTAT3 level. (A-D) Over-expression of PTPMeg2 decreases the tumor growth
of v-Src transformed fibroblasts. (A) v-Src activated pSTAT3 was decreased by Ad/PTPMeg2. A Western blot was used to show the indicated
proteins. STAT3 and pSTAT3 were examined in separated membranes from the same lysates. (B-D) 5 × 105 v-Src/NIH3T3 cells infected with Ad/
PTPMeg2 or Ad/GFP were used to inject s.c. into the right (Ad/PTPMeg2) and left (Ad/GFP) flanks of 6-week-old male nude mice (n = 5).
Xenograft tumors (B), tumor weights (C) and tumor volumes (D) are shown. (E) Over-expression of PTPMeg2 decreases the STAT3+/+ cell
proliferation. Mouse hepatic STAT3+/+ and STAT3+/+cells infected with the indicated adenovirus were used to examine the proliferation rate by
an MTT assay. Results were averaged from three repeats. (F) A Western blot was used to show the indicated proteins. (G) A high level of pSTAT3
is correlated with a low expression of PTPMeg2 in the breast carcinoma. Representative images of immunohistochemical staining of PTPMeg2,
pSTAT3 and STAT3 are shown. All the tumor tissues were derived from surgery sections. Peri-tumor (P) or tumor (T) tissues are marked with
dotted lines. Scale bars, 50 μm.
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data, these results suggested that the ability of PTPMeg2
to inhibit the tumor growth and cell proliferation is
depending on its role of regulation of phosphorylated
STAT3.
In consistence with the tumor growth experiment, we
examined the expression of STAT3 downstream genes.
The result showed that both Bcl-xL and cyclin D1 were
dramatically increased when PTPMeg2 was depleted in
MCF7 cells (Figure 4B). In contact, Bcl-xL and cyclin
D1 were decreased when PTPMeg2 was over-expressed
in MDA-MB-231 cells (Figure 4G). We observed no
alteration of STAT3 expression but the phosphorylated
STAT3 level was changed with either over-expression or
depletion of PTPMeg2 (Figure 4B, G). These results sug-
gest that PTPMeg2 regulates STAT3 phosphorylation
and thereafter the downstream gene expression.
To address whether PTPMeg2 regulates STAT3 depho-
sphorylation in human tumors, we examined the correla-
tion of pSTAT3 level and expression of PTPMeg2 in
human breast cancers. The result showed that expression
of PTPMeg2 was in a strong positive status in peritu-
moral tissues (90% = 37/41) and in a negative status in
paired tumor tissues (83% = 59/71) (Figure 5E, Table 1).
In contrast, pSTAT3 remained at a low (or negative)
level in the peritumoral tissues but at a high level (71% =
52/73) in the paired tumor tissues (Figure 5E). We
observed a negative correlation between PTPMeg2
expression and the pSTAT3 level (spearman’s correlation
coefficient was -3.33, p = 0.004, Table 2) from a Spear-
man’s correlation test. The analysis also revealed that the
increased STAT3 level was correlated with reduced
PTPMeg2 expression in the breast carcinoma (correla-
tion coefficient is -2.65, p = 0.023, Table 2). These data
indicated that PTPMeg2 might be an important regulator
of STAT3 dephosphorylation in tumors.
Discussion
Targeting pSTAT3 has becoming an important strategy
for cancer therapies [29] since hyper-phosphorylation of
STAT3 at tyrosine residues is associated with various
types of human cancers including breast cancer. The
hyper-phosphorylated STAT3 was caused by either the
over-activation of tyrosine kinases or the impaired func-
tion of tyrosine phosphatases. While many kinases have
been reported to activate STAT3 in tumors, it is still
interesting to identify a direct STAT3 phosphatase. In
this study, we found that PTPMeg2 is a strong phospha-
tase directly interacting with STAT3 and mediating
STAT3 dephosphorylation.
We have presented several lines of evidence demonstrat-
ing STAT3 is a substrate of PTPMeg2. First, PTPMeg2
physically and pathologically interacts with STAT3. Signif-
icantly, PTPMeg2 exhibits a strong affinity for pSTAT3
and STAT3. Next, PTPMeg2 dephosphorylated pSTAT3
in time- and dose-dependent manners. Third, the catalyti-
cally inactive mutant of PTPMeg2 lost the negative role in
pSTAT3. Fourth, deletion of the lipid-binding domain of
PTPMeg2 has no effect on the dephosphorylation. On the
contrary, depleting PTPMeg2 enhances the level of
pSTAT3 in cells and results in the cell proliferation and
tumor growth in nude mice. Consistent with the biochem-
istry and cellular biology data, we observed that the nega-
tive correlation between the expression of PTPMeg2 and
pSTAT3 in human breast cancer samples. All the results
are consistent and intercomparable in demonstrating the
role of PTPMeg2 in regulation of STAT3 activity in the
breast cancer. However, we can not exclude the possibility
that PTPMeg2 may target other substance. In this study,
we demonstrated that the inhibitory role of PTPMeg2 on
tumor growth was mainly through dephosphorylation of
STAT3.
Table 1 The expression level of PTPMeg2 in the breast
cancer samples
PTPMeg2 positive PTPMeg2 negative Total
Tumor 14 59 73
Peri-tumor 37 4 41
total 51 63 114
X2 = 53.262, p = 0.000
Table 2 Correlation of pSTAT3 with PTPMeg2 expression
in breast cancer
PTPMeg2
number negative weak strong correlation
coefficient
P*
pSTAT3 73 r = - 3.33** 0.004
negative 12 6 5 1
Weak 9 7 1 1
strong 52 46 5 1
STAT3 73 r = - 2.65* 0.023
negative 4 1 3 0
Weak 4 3 1 0
strong 65 55 7 3
ER 60 r = 0.280 0.834
negative 23 20 3 0
Weak 11 9 2 0
strong 26 22 4 0
PR 60 r = 0.212 0.105
negative 25 23 2 0
Weak 19 14 2 0
strong 14 14 5 0
Her2 70 r = - 1.53 0.203
negative 25 20 5 0
Weak 10 9 1 1
strong 35 32 3 0
r* < 0.05, r** < 0.01.
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Previous studies reported that several PTPs such as
PTPN1, PTPN3, and PTPN6 [30] have oncogenic prop-
erties but other PTPs including PTPN12 [31] have
tumor suppressor features. In this study, we found that
PTPMeg2 is a tumor repressor preferentially depho-
sphorylating STAT3. We have used several cell models
to demonstrate that enforced expression of PTPMeg2
inhibited tumor cell growth and depletion of PTPMeg2
resulted in enlarged tumors. Intriguingly we found that
the expression of PTPMeg2 was negative in human
breast cancer while it remained high in the peritumoral
tissues. This expression pattern is similar to that of
PTPN7 [32] and PTPN13 [33], which were reported to
be at a global loss in a wide range of cancers including
breast, kidney, and esophageal cancers. Recently,
PTPN13 was reported to loss its activity through
somatic mutations, allelic loss, or promoter methylation
in some tumors [34]. Whether PTPMeg2 has such a
kind of mutations in tumors remains unclear.
It has reported that PTPL1/PTPN13 regulated breast
cancer cell aggressiveness through a direct inactivation
of Src kinase [33] and PTPN12 inhibits breast cancer
metastasis through multiple targets including EGFR1,
Her2 and Src kinase [31]. A previous study reported
that PTPMeg2 targets EGFR and Her2 [20]. In this
study, we found that PTPMeg2 directly interacts with
STAT3. Interestingly, when we used v-Src to activate
STAT3 phosphorylation, we observed that PTPMeg2
strongly mediated dephosphorylation of STAT3 (Figure
5). However, we did not observe any interaction of v-Src
with PTPMeg2. This result implies that PTPMeg2
directly targets STAT3 activated by v-Src. Since STAT3
associates with EGFR or Her2, it is possible that
PTPMeg2 interacts with the STAT3/EGFR complex, as
observed by a previous study [20]. Whether the interac-
tion of PTPMeg2 with STAT3 requires other partners
will be an interesting question in future studies.
Another interesting observation is that PTPMeg2
mediates dephosphorylation of STAT3 at residue
Try705 while is has no effect of the phosphorylation of
STAT3 at residue Ser727. This seems reasonable since
PTPMeg2 is in the family of protein tyrosine phospha-
tases. We predict that the dephosphorylation of STAT3
at other non tyrosine residues is likely mediated by
other phosphatases to be further identified.
Conclusion
In summery, we demonstrated that the cytoplasmic
phosphatase PTPMeg2 directly mediates the depho-
sphorylation of pSTAT3 and negatively regulates
STAT3 activity. Down regulated expression of PTPMeg2
is correlated with elevated phosphorylated STAT3 in
human breast cancer tissues. Recovery of PTPMeg2 by
adenovirus/retrovirus results in tumor regression in
nude mouse models.
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